Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Immunogen

Unleash Gain Potential With 3 Pharma Stocks to Consider

With an increasing demand for treatments of chronic diseases, heightened investments in research and development, and the widespread integration of technology, the pharma industry is primed for success. Amid the solid industry prospects, let’s analyze the gain potential of three pharma stocks: Amneal Pharmaceuticals (AMRX), AbbVie Inc. (ABBV), and GSK…

Analyzing December Profit Potential for the Top 4 Pharma Stocks

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie To Buy ImmunoGen, Cancer Drug Maker, In $10.1 Billion Cash Deal

AbbVie agreed to buy ImmunoGen for $10.1 billion in cash, offering a rich premium for the maker of ovarian cancer treatment drug Elahere.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Biotech Leader ImmunoGen Eyes Early Buy Point Amid Path To Profitability

Among the best stocks to buy and watch, ovarian cancer treatment leader ImmunoGen is approaching an early buy point in today's stock market.

Investors Business Daily

These 7 Stocks Are Outperforming Nvidia In 2023

Nvidia stock has tripled, but it's not No. 1 in 2023. Carvana has surged 996%, leading seven huge winners this year.

Investors Business Daily

ImmunoGen, Day One Surge On Cancer Drug Updates, But Arcus Dips

ImmunoGen and Day One unveiled promising cancer treatment updates over the weekend, leading IMGN stock and DAWN stock to soar Monday.

Investors Business Daily

Immunogen Stock Shows Market Leadership With Jump To 99 RS Rating

Immunogen sees its Relative Strength Rating reach the elite 90-plus level.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Immunogen's Return On Capital Employed Overview

Immunogen's Return On Capital Employed Overview

According to Benzinga Pro data, during Q1, Immunogen (NASDAQ:IMGN) posted sales of $38.08 million. Earnings were up 35.05%, but Immunogen still reported an overall loss of $24.14 million.

What's Going On With ImmunoGen Shares Today?

What's Going On With ImmunoGen Shares Today?

ImmunoGen, Inc. (NASDAQ: IMGN) shares are trading flat at $3.57 after the company's Biologics License Application to treat ovarian cancer was accepted by the FDA with priority review.

Immunogen: Q1 Earnings Insights

Immunogen: Q1 Earnings Insights

Immunogen (NASDAQ:IMGN) reported its Q1 earnings results on Friday, May 6, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Immunogen Earnings Preview

Immunogen Earnings Preview

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-05-06. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-0.21.

Immunogen: Q4 Earnings Insights

Immunogen: Q4 Earnings Insights

Immunogen (NASDAQ:IMGN) reported its Q4 earnings results on Friday, February 25, 2022 at 06:30 AM. Here's what investors need to know about the announcement. Earnings Immunogen reported an EPS of $-0.17.

Earnings Outlook For Immunogen

Earnings Outlook For Immunogen

Immunogen (NASDAQ:IMGN) is set to give its latest quarterly earnings report on Friday, 2022-02-25. Here's what investors need to know before the announcement. Analysts estimate that Immunogen will report an earnings per share (EPS) of $-1.71.

1

Organisations

Super Micro Computer

Medical Pharmaceuticals

BristolMyers Squibb Company

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Topics

inkl

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play